Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y12 inhibition
Nicolas Bourguet(Eli Lilly (United States)), Maxime Moulard(Compagnie Maritime d'Expertises (France)), Danièle Boulay-Moine(Compagnie Maritime d'Expertises (France)), Paul Barragan(Hôpital Privé Marseille Beauregard), Chunmei Zhou(Eli Lilly (United States)), Shinji Yamaguchi(Daiichi-Sankyo (Japan)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom))
Cited by 21
Related Papers
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
|New England Journal of Medicine|2002|4k
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617